Anthrax vaccine instructions for use. Anthrax vaccine: features of use, instructions

06.04.2020 -

Anthrax vaccine

Live anthrax vaccine:: Pharmacological action

After a double application with an interval of 20-30 days, it causes the formation of a tense immunity lasting up to 1 year.

Live anthrax vaccine:: Indications

Specific prophylaxis of anthrax: persons working with live cultures of the anthrax pathogen, with infected laboratory animals or conducting research on materials contaminated with the anthrax pathogen; persons engaged in slaughtering, harvesting, collecting, storing, transporting, processing and selling raw materials of animal origin; persons performing work in anthrax-enzootic territories (maintenance of social livestock, agricultural, agro-and hydro-reclamation, construction and other works related to excavation and movement of soil, procurement, commercial, geological, prospecting, expeditionary work).

Live anthrax vaccine:: Contraindications

Acute (infectious and non-infectious) diseases (vaccination is carried out no earlier than 1 month after recovery or remission), immunodeficiency (primary and secondary), simultaneous administration of corticosteroids, antimetabolites, radiation therapy (vaccination is carried out no earlier than 6 months after the end of therapy), malignant neoplasms and malignant blood diseases, systemic connective tissue diseases, common recurrent skin diseases, diseases of the endocrine system, pregnancy, lactation, children's age (up to 14 years).

Anthrax live vaccine:: Side effects

When applied to the skin, a local reaction appears after 24-48 hours: hyperemia, a small infiltrate, followed by the formation of a yellowish crust along the notches. With syringe and needleless methods of administration, after 24-48 hours at the injection site - soreness, hyperemia, less often - an infiltrate with a diameter of up to 50 mm. A general reaction with cutaneous and s / c administration of the vaccine rarely occurs on the first day after administration: malaise, headache, slight fever. Sometimes there may be an increase in body temperature up to 38.5 degrees C and a slight increase in regional lymph nodes.

Anthrax live vaccine:: Dosage and administration

Skin (scarification) and s / c. It is advisable to carry out unscheduled vaccination s / c. Primary immunization is carried out twice with an interval of 20-30 days, revaccination is carried out once annually. Cutaneous dose of the vaccine - 0.05 ml (contains 500 million spores), one s / c dose - 0.5 ml (50 million spores). Skin (scarification): immediately before use, the contents of the ampoule are resuspended in a sterile 30% aqueous solution of glycerol, which is introduced into the ampoule using a syringe with a needle for intramuscular injection. The volume of the solvent is determined by the number of vaccination doses in the ampoule. In an ampoule with 10 skin doses, 0.5 ml is added, and with 20 skin doses, 1 ml of the solvent. The ampoule is shaken until a homogeneous suspension is formed. The dissolution time of the vaccine should not exceed 5 minutes. The diluted vaccine from an opened ampoule, stored under aseptic conditions, can be used for 4 hours. Vaccination is carried out on the outer surface of the middle third of the shoulder. The vaccination site is treated with ethanol or a mixture of ethanol and ether. The use of other disinfectant solutions is not allowed. After evaporation of ethanol and ether with a sterile tuberculin syringe with a thin and short needle (N 0415), without touching the skin, one drop (0.025 ml) of the diluted vaccine is applied to 2 places of future incisions at a distance of 3-4 cm. The skin is slightly stretched and sterile with a smallpox pen, through each drop of the vaccine, 2 parallel notches 10 mm long are made so that they do not bleed (blood should only come out in the form of small ones). With the flat side of the vaccinating pen, the vaccine is rubbed into the notches for 30 seconds and allowed to dry for 5-10 minutes. For each grafted use a separate disposable pen. It is forbidden to use needles, scalpels, etc. instead of feathers. S / c: the vaccine is resuspended in 1 ml of sterile 0.9% NaCl solution immediately before use. The ampoule is shaken until a uniform suspension is formed. The contents of the ampoule are transferred with a sterile syringe into a sterile vial with 0.9% NaCl solution. In the case of using an ampoule containing 200 s / c inoculation doses, the suspension is transferred into a vial with 99 ml, and containing 100 s / c inoculation doses - into a vial with 49 ml of solvent. With the syringe method, the vaccine is injected into the region of the lower angle of the scapula at a dose of 0.5 ml. The skin at the injection site is treated with ethanol or a mixture of ethanol and ether. For each vaccinated, a disposable syringe and needle is used. Shake the vial before each selection of the vaccine. The injection site is lubricated with 5% tincture of iodine. When using the vaccine s / c in a needleless way, the vaccine is injected in a volume of 0.5 ml into the area of the outer surface of the upper third of the shoulder with a needleless injector with a protector, with strict observance of the instructions for their use. The injection site is treated before and after the injection, as with the syringe method.

Live anthrax vaccine:: Special instructions

It is strictly forbidden to administer s / c vaccine diluted for cutaneous use! In order to identify contraindications, the doctor (paramedic) on the day of vaccination conducts a survey and examination of the vaccinated with mandatory thermometry. In each individual case, for diseases not included in this list of contraindications, vaccination is carried out only with the permission of the relevant specialist doctor. In a planned manner, vaccination is carried out by the skin method in the first quarter of the year, because. the most dangerous in relation to infection with anthrax in disadvantaged areas is the spring-summer season. Vaccination is carried out by paramedical personnel under the guidance of a doctor. Before use, each ampoule with the vaccine is carefully examined. The vaccine should not be used if the integrity of the ampoule is damaged, the appearance of the dry and dissolved preparation changes (foreign particles, unbroken lumps and flakes), the label is missing, the expiration date has expired, or the storage regime is violated. Unused vaccine, used disposable vaccination syringes and pens are subject to mandatory inactivation by autoclaving at a temperature of (132+2) degrees C and a pressure of 2 kgf/sq.m for 90 minutes. Parts of the needleless injector that came into contact with the vaccine, after pre-treatment, are immersed in a 6% hydrogen peroxide solution with 0.5% detergent type or for 1 hour at a temperature not lower than 50 degrees C. The solution is used once. Parts of the injector are sterilized by autoclaving at a temperature of (132+2) degrees C and a pressure of 2 kgf/sq.m for 90 minutes.

Live anthrax vaccine :: Interaction

The interval between vaccination against anthrax and the introduction of other vaccines should be at least 1 month.

Skin (scarification) and s / c.
It is advisable to carry out unscheduled vaccination s / c.
Primary immunization is carried out twice with an interval of 20-30 days, revaccination is carried out once annually. The skin dose of the vaccine is 0.05 ml (contains 500 million spores), one s / c dose is 0.5 ml (50 million spores).
Skin (scarification): immediately before use, the contents of the ampoule are resuspended in a sterile 30% aqueous solution of glycerol, which is introduced into the ampoule using a syringe with a needle for intramuscular injection. The volume of the solvent is determined by the number of vaccination doses in the ampoule. In an ampoule with 10 skin doses, 0.5 ml is added, and with 20 skin doses, 1 ml of the solvent. The ampoule is shaken until a homogeneous suspension is formed. The dissolution time of the vaccine should not exceed 5 minutes. The diluted vaccine from an opened ampoule, stored under aseptic conditions, can be used for 4 hours. Vaccination is carried out on the outer surface of the middle third of the shoulder. The vaccination site is treated with ethanol or a mixture of ethanol and ether. The use of other disinfectant solutions is not allowed. After evaporation of ethanol and ether with a sterile tuberculin syringe with a thin and short needle (No. 0415), without touching the skin, one drop (0.025 ml) of the diluted vaccine is applied to 2 places of future incisions at a distance of 3-4 cm. The skin is slightly stretched and sterile with a smallpox pen through each drop of the vaccine, 2 parallel notches 10 mm long are made so that they do not bleed (blood should appear only in the form of small “dewdrops”). With the flat side of the vaccinating pen, the vaccine is rubbed into the notches for 30 seconds and allowed to dry for 5-10 minutes. For each grafted use a separate disposable pen. It is forbidden to use needles, scalpels, etc. instead of feathers.
S / c: the vaccine is resuspended in 1 ml of sterile 0.9% NaCl solution immediately before use. The ampoule is shaken until a uniform suspension is formed. The contents of the ampoule are transferred with a sterile syringe into a sterile vial with 0.9% NaCl solution. In the case of using an ampoule containing 200 s / c inoculation doses, the suspension is transferred into a vial with 99 ml, and containing 100 s / c inoculation doses - into a vial with 49 ml of solvent.
With the syringe method, the vaccine is injected into the region of the lower angle of the scapula at a dose of 0.5 ml. The skin at the injection site is treated with ethanol or a mixture of ethanol and ether. For each vaccinated, a disposable syringe and needle is used. Shake the vial before each selection of the vaccine. The injection site is lubricated with 5% tincture of iodine.
When using the vaccine s / c in a needleless way, the vaccine is injected in a volume of 0.5 ml into the area of the outer surface of the upper third of the shoulder with a needleless injector with a protector, with strict observance of the instructions for their use.
The injection site is treated before and after the injection, as with the syringe method.

Anthrax vaccine

Instructions for use of live dry anthrax vaccine for subcutaneous and scarification use

The vaccine is live spores of the vaccine anthrax strain STI, lyophilized in a 10% aqueous solution of sucrose, has the form of a homogeneous porous mass of grayish-white or yellowish-white color.

Immunological properties

Anthrax live dry vaccine after double application with an interval of 20 ... 30 days causes the formation of intense immunity lasting up to 1 year.

Purpose

Specific prevention of anthrax from the age of 14.

persons working with live cultures of the anthrax agent, with infected laboratory animals or conducting research on materials contaminated with the anthrax agent;
persons engaged in slaughtering, harvesting, collecting, storing, transporting, processing and selling raw materials of animal origin;
persons performing the following work in anthrax enzootic territories:
- maintenance of public livestock;
- agricultural, agro- and hydro-reclamation, construction and other works related to the excavation and movement of soil;
- procurement, commercial, geological, prospecting, forwarding.

In a planned manner, vaccination is carried out by the skin method in the first quarter of the year, since the most dangerous in relation to infection with anthrax in disadvantaged areas is the spring-summer season.

Method of application and dosage

The vaccine is used by skin (scarification) and subcutaneous methods. It is expedient to carry out unscheduled vaccination by the subcutaneous method.

Primary immunization is carried out twice with an interval of 20 ... 30 days, revaccination is carried out once annually. For all vaccinations, the skin dose of the vaccine is 0.05 ml and contains 500 million spores, one subcutaneous dose of 0.5 ml contains 50 million spores.

Each vial of vaccine is carefully inspected before use. The vaccine should not be used: if the integrity of the ampoule is damaged, if the appearance of the dry and dissolved preparation changes (foreign particles, unbroken lumps and flakes), if there is no label, after the expiration date, if the storage regime has been violated.

Vaccination by skin (scarification) method

Immediately before use, the contents of the ampoule are resuspended in a sterile 30% aqueous solution of glycerol, which is introduced into the ampoule using a syringe with a needle for intramuscular injection. The volume of the solvent is determined by the number of vaccination doses in the ampoule. In an ampoule with 10 skin doses, 0.5 ml is added, and with 20 skin doses, 1.0 ml of the solvent. The ampoule is shaken until a homogeneous suspension is formed. The dissolution time of the vaccine should not exceed 5 minutes. The diluted vaccine from an opened ampoule, stored under aseptic conditions, can be used for 4 hours. The vaccination is carried out on the outer surface of the middle third of the shoulder. The vaccination site is treated with alcohol or a mixture of alcohol and ether. The use of other disinfectant solutions is not allowed. After evaporation of alcohol and ether with a sterile tuberculin syringe with a thin and short needle (No. 0415), without touching the skin, one drop (0.025 ml) of the diluted vaccine is applied to 2 places of future incisions at a distance of 3 ... 4 cm. Skin slightly stretch and with a sterile smallpox grafting pen, through each drop of the vaccine, 2 parallel notches 10 mm long are made so that they do not bleed (blood should appear only in the form of small dewdrops). With the flat side of the smallpox grafting pen, the vaccine is rubbed into the notches for 30 seconds and allowed to dry for 5-10 minutes. For each grafted use a separate disposable pen. It is forbidden to use needles, scalpels, etc. instead of feathers.

Vaccination by subcutaneous method

The drug is resuspended in 1.0 ml of sterile 0.9% sodium chloride solution immediately before use. The ampoule is shaken until a uniform suspension is formed. The contents of the ampoule are transferred with a sterile syringe into a sterile vial with 0.9% sodium chloride solution for injection. In the case of using an ampoule containing 200 subcutaneous inoculation doses, the suspension is transferred into a vial with 99 ml, and containing 100 subcutaneous inoculation doses - into a vial with 49 ml of solvent.

In the syringe method, the vaccine is injected into the region of the lower angle of the scapula. The skin at the injection site is treated with alcohol or a mixture of alcohol and ether. The vaccine in a volume of 0.5 ml is administered subcutaneously. A disposable syringe and needle is used for each vaccinated person. Shake the vial before each selection of the vaccine. The injection site is lubricated with 5% tincture of iodine.

When using the vaccine by the subcutaneous needle-free method, the spore suspension is injected in a volume of 0.5 ml into the region of the outer surface of the upper third of the arm with a needle-free injector with a protector, strictly following the instructions for their use. The injection site is treated before and after the injection, as with the syringe method.

Unused vaccine, used grafting disposable syringes and pens are subject to mandatory inactivation by autoclaving at a temperature of (132 ± 2)°C and a pressure of 2.0 kgf/m 2 for 90 minutes.

The parts of the needleless injector in contact with the vaccine, after pre-treatment, are immersed in a 6% hydrogen peroxide solution with 0.5% Progress or Astra detergent for 1 hour at a temperature not lower than 50 °C. The solution is used once.

Parts of the injector are sterilized by autoclaving at a temperature of (132 ± 2) ° C and a pressure of 2.0 kgf / m 2 for 90 minutes.

Reaction to the introduction

When applied to the skin, a local reaction appears after 24...48 hours in the form of hyperemia, a small infiltrate, followed by the formation of a yellowish crust along the incisions. With a syringe and needleless methods of administration, after 24 ... 48 hours at the injection site there may be a slight soreness, hyperemia, less often - an infiltrate with a diameter of up to 50 mm.

A general reaction with cutaneous and subcutaneous administration of the vaccine rarely occurs on the first day after vaccination and is manifested by malaise, headache and a slight increase in temperature. Sometimes there may be an increase in body temperature up to 38.5 ° C and a slight increase in regional lymph nodes.

Contraindications

Acute infectious and non-infectious diseases - vaccinations are carried out no earlier than 1 month after recovery (remission).
Primary and secondary immunodeficiencies. When treating with steroids, antimetabolites, X-ray therapy, vaccinations are carried out no earlier than 6 months after the end of therapy.
Malignant neoplasms and malignant diseases of the blood.
Systemic connective tissue diseases.
Common recurrent skin diseases.
Diseases of the endocrine system.
Pregnancy and lactation.

In each individual case, for diseases not included in this list, vaccination is carried out only with the permission of the relevant specialist doctor.

The interval between anthrax vaccination and other vaccines must be at least one month. In order to identify contraindications, the doctor (paramedic) on the day of vaccination conducts a survey and examination of the vaccinated with mandatory thermometry.

Vaccinations are carried out by paramedical personnel under the guidance of a physician.

Release form

1.0 ml of vaccine in an ampoule containing 200 human doses for subcutaneous or 20 human doses for skin vaccination with 1.5 ml of solvent for cutaneous application - 30% aqueous solution of glycerin.

1.0 ml of vaccine in an ampoule containing 100 human doses for subcutaneous or 10 human doses for cutaneous vaccination with 1.0 ml of solvent for dermal application - 30% aqueous solution of glycerin.

The package contains 5 ampoules of the vaccine and 5 ampoules of the solvent

Storage and transportation conditions

The vaccine is stored and transported in accordance with SP 3. 3. 2. 028-95 at a temperature of 2 to 10 °C. Transportation can also be carried out at a temperature not exceeding 25 °C for no more than 20 days.

Best before date

Vaccine produced under vacuum - 4 years; produced without vacuum - 3 years.

Ministry of Defense of the Russian Federation, Russia

Release form: 1 ampoule/10 doses #5
Vaccination schedule: double 0 day - 20 day or 30 day.
Revaccination once a year.

Instructions for use

Registration certificate holder:

48 Central Research Institute of the Ministry of Defense of the Russian Federation FGU (Russia)

ATX code: J07AC01 (Anthrax antigen)

Dosage form

reg. No.: R N001273/01 dated 09/02/14 - Indefinitely

Release form, composition and packaging

in the form of a porous mass of grayish-white or yellowish-white color with a brownish tint.

Excipients

Solvent composition: 30% solution of glycerol.

100 subcutaneous or 10 cutaneous inoculation doses - ampoules (5) complete with a solvent (1 ml amp. 5 pcs.) - cardboard packs.

Lyophilizate for the preparation of a suspension for s / c administration and skin scarification application in the form of a porous mass of grayish-white or yellowish-white color with a brownish tint.

Excipients: sucrose - 10% solution (stabilizer).

Solvent composition: 30% solution of glycerol.

200 subcutaneous or 20 cutaneous inoculation doses - ampoules (5) complete with a solvent (1 ml amp. 5 pcs.) - cardboard packs.

Clinico-pharmacological group: Vaccine for the prevention of anthrax

Pharmacotherapeutic group: MIBP vaccine

pharmachologic effect

The live anthrax vaccine after a double application with an interval of 20-30 days causes the formation of specific immunity lasting up to 1 year.

Indications

Specific prophylaxis of anthrax in people over 14 years of age. Vaccination is carried out in a planned manner and according to epidemic indications.

Scheduled vaccinations are subject to:

persons working with live cultures of the anthrax agent, with infected laboratory animals or conducting research on materials contaminated with the anthrax agent;
persons engaged in slaughtering, harvesting, collecting, storing, transporting, processing and selling raw materials of animal origin;
persons performing the following work in anthrax enzootic areas:
maintenance of community livestock;
agricultural, agro- and hydro-reclamation, construction and other works related to the excavation and movement of soil;
procurement, commercial, geological, prospecting, forwarding.

In a planned manner, vaccination is carried out in the first quarter of the year, because. the most dangerous in relation to infection with anthrax in disadvantaged areas is the spring-summer season.

Dosing regimen

Vaccination is carried out by paramedical personnel under the guidance of a doctor.

Scheduled vaccination. Primary immunization is carried out by the scarifying method twice with an interval of 20-30 days, revaccination - once annually by the subcutaneous method.

Vaccination according to epidemic indications is carried out subcutaneously. If necessary, revaccination is carried out once annually by the subcutaneous method.

Before use, each ampoule with the vaccine is carefully examined. The vaccine should not be used if the integrity of the ampoule is damaged, the appearance of the dry and dissolved preparation changes (the presence of foreign inclusions, non-breakable lumps and flakes), there is no label, the expiration date has expired, or the storage regime has been violated.

1. Vaccination by skin (scarification) method.

Based on the number of inoculation doses, the contents of the ampoule (vial) immediately before use are resuspended in a solvent - a sterile 30% aqueous solution of glycerol using a syringe with a needle for intramuscular injection (No. 0840). In an ampoule (vial) with 10 skin doses add 0.5 ml, and with 20 skin doses - 1.0 ml of the solvent and shake until a homogeneous suspension of a grayish-white or yellowish-white color with a brownish tint is formed. The dissolution time of the vaccine should not exceed 5 minutes. The diluted vaccine, stored under aseptic conditions, can be used within 4 hours.

The vaccination is made on the outer surface of the middle third of the shoulder. The vaccination site is treated with 70% alcohol. The use of other disinfectant solutions is not allowed. After evaporation of the alcohol with a sterile tuberculin syringe with a thin and short needle (No. 0415), without touching the skin, one drop (0.025 ml) of the diluted vaccine is applied to 2 places of future incisions at a distance of 3-4 cm on the horizontally located surface of the shoulder. The skin is slightly stretched and with a sterile smallpox grafting pen, 2 parallel incisions (at a distance of 3-5 mm) 10 mm long are made through each drop of the vaccine so that they do not bleed (blood can only appear in the form of small dewdrops). With the flat side of the smallpox feather, the vaccine is rubbed into the notches for 30 seconds and allowed to dry for 5-10 minutes. / For each grafted use a separate disposable pen. It is forbidden to use needles, scalpels, etc. instead of feathers. P.

2. Vaccination by subcutaneous method.

The drug is resuspended in 1 ml of sterile sodium chloride solution 0.9% immediately before use. The ampoule (bottle) is shaken until a uniform suspension of a grayish-white or yellowish-white color with a brownish tint is formed. The contents of the ampoule (vial) are transferred with a sterile syringe into a sterile vial with sodium chloride solution of 0.9% for injection. In the case of using an ampoule (vial) containing 200 subcutaneous inoculation doses, the suspension is transferred into a vial with 99 ml, and containing 100 subcutaneous inoculation doses - into a vial with 49 ml of solvent.

With the syringe method, the vaccine in a volume of 0.5 ml is injected subcutaneously into the region of the lower angle of the scapula. The skin at the injection site is treated with 70% alcohol. Shake the vial before each selection of the vaccine. The injection site is lubricated with 5% tincture of iodine. With the needleless method, the vaccine in a volume of 0.5 ml is injected into the area of the outer surface of the upper third of the shoulder with a needleless injector with a protector, strictly following the instructions for their use. The place of administration of the vaccine before and after the injection is treated, as in the subcutaneous method.

Unused vaccine, used disposable vaccination syringes and pens are subject to mandatory inactivation by autoclaving at a temperature of (132+2)°C and a pressure of 2.0 kgf/m for 90 minutes.

The parts of the needleless injector that come into contact with the vaccine are immersed in a 6% hydrogen peroxide solution with the addition of 0.5% Progress or Astra detergent for 1 hour at a temperature not lower than 50°C. The solution is used once. Then the pre-sterilization treatment of the injector is carried out:

a) rinsing under running water for 0.5 minutes;

b) soaking with full immersion in a washing solution at a temperature of 50 ° C for 15 minutes. Recipe 1 liter of detergent solution: 17 g of perhydrol (27.5 g of 33% hydrogen peroxide), 5 g of detergent and 978 ml of water;

c) washing in a detergent solution with a brush or cotton-gauze swab

each item for 0.5 min;

d) rinsing under running water for 10 minutes;

e) rinsing with distilled water for 0.5 minutes of each item;

e) drying until complete disappearance of moisture.

Sterilization of parts of the needleless injector is carried out by autoclaving at a temperature of (132±2)°C and a pressure of 2.0 kgf/m2 for 90 minutes.

Side effect

It can manifest itself on the first day after vaccination with malaise, headache and fever up to 38.5 ° C.

Reaction to the introduction

Vaccine vaccinations may be accompanied by local reactions, the intensity of which depends on the individual characteristics of the vaccinated. 24-48 hours after skin vaccination, hyperemia, infiltration may occur at the injection site, followed by the formation of yellowish crusts along the notches. 24-48 hours after subcutaneous vaccination, pain, hyperemia may occur at the injection site, less often - an infiltrate with a diameter of up to 50 mm.

Contraindications for use

acute infectious and non-infectious diseases - vaccinations are carried out no earlier than 1 month after recovery (remission);
primary and secondary immunodeficiencies. When treating with steroids, antimetabolites, X-ray therapy, vaccinations are carried out no earlier than 6 months after the end of therapy;
malignant neoplasms and malignant blood diseases;
systemic connective tissue diseases;
common recurrent skin diseases;
diseases of the endocrine system;
pregnancy and lactation;

In each individual case, for diseases not included in this list, vaccination is carried out only with the permission of the relevant specialist doctor.

In order to identify contraindications, the doctor (paramedic) on the day of vaccination conducts a survey and examination of the vaccinated with mandatory thermometry.

Use during pregnancy and lactation

Contraindicated during pregnancy and lactation.

drug interaction

The interval between vaccination against anthrax and the introduction of other vaccines must be at least one month, and in relation to children's contingents - at least two months. The vaccine is sensitive to antibiotics, and therefore immunization against the background of the use of antibiotics is not allowed.

Terms and conditions of storage

Store in accordance with SP 3.3.2.1248-03 at a temperature of 0 to 8°C out of the reach of children.

Shelf life in ampoules under vacuum - 4 years; in ampoules and vials without vacuum - 3 years.

Transported in accordance with SP 3.3.2.1248-03 at a temperature of 0 to 8°C. Transportation is allowed for up to 20 days at a temperature not exceeding 25°C.

Terms of dispensing from pharmacies

For treatment-and-prophylactic and sanitary-prophylactic institutions.

Everything you need to know about the Chinese coronavirus

RT TV interview with Dmitry Lvov, a legend of Soviet virology, a WHO expert on influenza and respiratory infections since 1987.

There are several types of the virus, but serotypes A, B, C are pathogenic for humans, and type A is the most common. This virus affects not only humans, but also various species of mammals and birds. Group A rotavirus is considered one of the most common causes of infectious diarrhea in children.

Poliomyelitis is an acute infectious human disease, which is accompanied by damage to the nervous system, the development of paresis and paralysis. Poliomyelitis mainly affects children under 5 years of age. 1 in 200 infections results in permanent paralysis. Among those paralyzed, 5% to 10% die when their breathing muscles become immobile.

Many parents panic, confusing rotavirus, dysentery and poisoning. Doctors warn that one of the main differences is chair character.

This article was the result of an incredible effort by a group of ordinary people working around the clock to find all the relevant studies to structure them into a coherent whole, if it can help others process all the information available about the coronavirus.

Contains live spores of the STI-1 vaccine strain, freeze-dried in 10% sucrose solution. Named after the Sanitary-Technical Institute where it was developed. a resistant variant (mutant) of anthrax bacteria, devoid of a capsule and the ability to cause diseases in humans and animals, is used to make the vaccine. The drug is used to prevent anthrax according to epidemiological indications in people aged 14 to 60 years. Vaccination is carried out twice with an interval of 21 days, revaccination - annually, once. Vaccination is carried out by persons involved in the collection, storage, transportation and processing of raw materials of animal origin, as well as personnel involved in slaughter, butchering carcasses and skinning. The drug is administered subcutaneously or subcutaneously.

Vaccine anthrax combined liquid for subcutaneous use.

The drug is a mixture of live spores of the vaccine strain STI-1 anthrax microbe and purified, concentrated, protective anthrax antigen (PA) adsorbed on aluminum hydroxide. The vaccine is used to prevent anthrax in people 14 to 60 years of age. Vaccination is carried out once, the first three revaccinations are carried out with an interval of 1 year, the next three - with an interval of 2 years. Intense immunity is formed 7 days after the first injection of the vaccine: and persists for a year. The drug is administered subcutaneously.

Globulin anti-anthrax equine liquid.

Contains antibodies against anthrax. Upon receipt of the drug, horses are hyperimmunized, then fractions of gamma and beta globulins are isolated from blood serum by ethanol precipitation at low temperatures. Does not contain preservatives. Used for emergency prevention and treatment of patients with anthrax. The drug is administered intramuscularly. For prophylactic purposes, it is administered once (as soon as possible after the suspected infection), for therapeutic purposes - immediately after the diagnosis of anthrax within 3-4 days. Before using the drug, an intradermal test is necessary. With a positive test, globulin is administered only for health reasons under the supervision of a physician.

Preparations for the prevention and treatment of staphylococcal infections

Purified adsorbed staphylococcal anatoxin.

Contains 10 EU of staphylococcal toxoid in 1 ml. In the preparation of the preparation, staphylococcal toxin (contained in the filtrate of the staphylococcus broth culture) is neutralized with formalin and heat, precipitated with trichloroacetic acid, purified with ethyl alcohol and adsorbed on aluminum hydroxide. When toxoid is introduced into the body, it induces the formation of antitoxic antibodies. Used to prevent staphylococcal infections. The drug is administered:

a) workers at high risk of injury; b) patients undergoing elective surgery; c) pregnant women; d) donors to receive anti-staphylococcal plasma and anti-staphylococcal immunoglobulin. Anatoxin is injected subcutaneously, usually twice with an interval of 20-40 days.

Staphylococcal vaccine.

Contains a suspension of staphylococci in a 0.9% solution of aSi, inactivated by heating for 2 hours at 560 C. The vaccine is prepared from 10-12 coagulase-positive strains of staphylococcus isolated from patients. The preservative is phenol. The drug is used to treat adults with various diseases of staphylococcal and streptostaphylococcal etiology: recurrent furunculosis, pyoderma, panaritiums, confluent acne, etc. The vaccine is administered subcutaneously or intramuscularly.

Vaccine Staphylo-Protein-Pseudomonas aeruginosa adsorbed liquid.

It is a complex of purified, concentrated toxoids of staphylococcus aureus and Pseudomonas aeruginosa, cytoplasmic antigen of staphylococcus and chemical proteinaceous vaccine, adsorbed on aluminum hydroxide. The drug is used for active immunization of patients aged 18 - 60 years to prevent infections caused by staphylococci, Proteus and Pseudomonas aeruginosa. The vaccine should be administered to patients with injuries, burns, fractures, as well as in preoperative preparation.